Th17 Cells Retain Antitumor Efficacy after Expansion to Large Numbers Outside the Body (IMAGE)
Caption
CD8+ T cells and Th1 cells become exhausted and lose antitumor efficacy as they're expanded for adoptive cell therapy. Th17 cells are resistant to degradation (senescence) and retain their antitumor efficacy, resulting in large numbers of potent tumor-reactive T cells for patient treatment.
Credit
Image courtesy of Dr. Chrystal Paulos and Jacob Bower of the Medical University of South Carolina
Usage Restrictions
Use with appropriate caption and credit line
License
Licensed content